Novo Nordisk, WeightWatchers
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...
Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...
Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...
A committee report found the weight loss drug is offered for less than $100 in some European countries, compared to monthly ...
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...
The results suggest Ozempic could potentially become a new alternative treatment for opioid use disorder, which could help ...
Sharon Osbourne has opened up about using the popular weight loss injection Ozempic, including the little-known side effects.